Brand Name(s): Epivir; Epivir-HBV
CAS nº: 134678-17-4
(la mih vue deen)

About Lamivudine

This new site is dedicated exclusively to lamivudine.

It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.

Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about lamivudine on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.

This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total lamivudine experience! 

Why is this medication prescribed?

Lamivudine is an antiviral medication. It is in a group of human immunodeficiency virus (HIV) medicines called reverse transcriptase inhibitors. Lamivudine helps keep the HIV virus from reproducing in the body.

The Epivir® brand of lamivudine is used to treat HIV and hepatitis B viruses, which cause the acquired immunodeficiency syndrome (AIDS). On the other hand, the Epivir-HBV® brand of lamivudine is used to treat chronic hepatitis B. 

Lamivudine is not, however, a cure for HIV or AIDS.

See more Product Info

Latest News

Low-Dose Tenofovir Shows Efficacy in Patients With Lamivudine-Resistant Hepatitis B Virus: Presented at IM

Virologic breakthrough during hepatitis B virus (HBV) treatment with lamivudine is associated with...

[more]

HIV/AIDS Update - Epivir Tablets for Pediatric Dosing

FDA has approved a new formulation of Epivir (lamivudine) designed to facilitate dosing in...

[more]

What is the more suitable for early detection of low abundant lamivudine-resistant mutants?

Lamivudine is an effective antiviral agent for treatment of patients with chronic hepatitis B and...

[more]

WHO Adds Three Ranbaxy Antiretrovirals to Prequalification List

Indian pharmaceutical company Ranbaxy Laboratories on Monday announced that the World Health...

[more]

This site is intended solely for U.S. audiences; products described here may be subject to different medical and/or regulatory requirements in other countries. This site is for educational purposes only; information contained within should not be used to diagnose or treat a health problem or disease. Please consult a licensed health care provider regarding your medical condition.The products mentioned are trademarks of their respective owners.